From time to time new information about BiDil or new advances in the treatment of heart failure may become available. Complete the fields below to receive e-mail updates and alerts when new information becomes available at BiDil.com.

NitroMed respects your personal information. Please review our Privacy Policy.

Notice: If you are NOT a health care professional, click here to sign up for updates to our site for patients, family, and friends.

ENTER THE FOLLOWING INFORMATION AND CLICK "SUBMIT"

* Denotes required information.

*I am a:	Select Cardiologist Primary Care Physician Ob/Gyn Physician's Assistant Nurse Nurse Practitioner Health Educator Pharmacist Family Practitioner Internist Other
*First Name:
*Last Name:
*E-Mail:
*Confirm E-Mail:
*Security Code:	Write the characters in the image above

If you would like to receive information about heart failure or BiDil by mail, please include your mailing address.

Important information about BiDil®
(isosorbide dinitrate/hydralazine hydrochloride):

INDICATIONS AND USAGE
BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient reported functional status. There is little experience in patients with NYHA class IV heart failure. Most patients in the clinical trial supporting effectiveness (A-HeFT) received a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker, and many also received a cardiac glycoside or an aldosterone antagonist.

CONTRAINDICATIONS
BiDil is contraindicated in patients who are allergic to organic nitrates.

WARNINGS
Augmentation of the vasodilatory effects of isosorbide dinitrate by phosphodiesterase inhibitors such as sildenafil, vardenafil, or tadalafil could result in severe hypotension. The time course and dose dependence of this interaction have not been studied. Reasonable supportive care should consist of those measures used to treat a nitrate overdose with elevation of the extremities and central volume expansion.

ADVERSE REACTIONS
Adverse events reported in A-HeFT and seen more frequently in the group given BiDil included headache (50% in BiDil patients vs. 21% in placebo patients) and dizziness (32% in BiDil patients vs. 14% in placebo patients).

The full Prescribing Information for BiDil is available here.